Physician profile
Laura E Howe
NPI 1407053275
$13,403.71
in general payments reported to CMS, 2019-2025
43 companies · $3,036 in 2025
The $3,036 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $1,115 · 2021: $1,420 · 2022: $2,408 · 2023: $2,069 · 2024: $2,403 · 2025: $3,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,453 · Consulting Fee: $41.35 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,452.71 |
| Consulting Fee | $41.35 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,012.84 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,071.65 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,106.95 | 2019-2025 | |
| Amgen INC. | $827.73 | 2021-2025 | Tezspire |
| Csl Behring | $748.48 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Regeneron Healthcare Solutions, INC. | $680.45 | 2019-2025 | Dupixent |
| Pfizer INC. | $586.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $543.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $523.80 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Genentech USA, INC. | $493.38 | 2019-2025 | Xolair |
| Abbvie INC. | $340.67 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.96 | 2020-2023 | Spiriva Respimat, Stiolto Respimat |
| Biocryst US Sales Co., LLC | $224.98 | 2022-2024 | Orladeyo |
| Blueprint Medicines Corporation | $208.18 | 2023-2024 | Ayvakit |
| Pharming Healthcare, INC. | $202.43 | 2022-2024 | Joenja, Ruconest |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $182.68 | 2019-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $164.34 | 2019-2023 | Airduo Digihaler |
| Aimmune Therapeutics, INC. | $133.08 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $127.24 | 2025 | Neffy |
| Genentech, INC. | $116.17 | 2022 | |
| Organon LLC | $106.92 | 2025 | Vtama |
| Adma Biomanufacturing LLC | $74.23 | 2021-2024 | |
| Alk-Abello, INC | $59.99 | 2022-2025 | Pre-Pen, Standardized Mite D. Farinae, Timothy, Standardized |
| Welch Allyn | $58.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2022 | |
| Ionis Pharmaceuticals, INC. | $57.17 | 2025 | Dawnzera |
| Incyte Corporation | $47.33 | 2025 | Opzelura |
| Grifols USA, LLC | $44.03 | 2021-2023 | Xembify |
| Octapharma USA, INC. | $42.08 | 2021-2024 | Cutaquig |
| Lilly USA, LLC | $37.31 | 2024 | Ebglyss, Taltz |
| Greer Laboratories, INC. | $35.10 | 2024-2025 | Palforzia, Oralair |
| Leo Pharma INC. | $31.89 | 2023-2025 | Anzupgo, Adbry |
| Merck Sharp & Dohme LLC | $31.54 | 2021-2023 | |
| Shire North American Group INC | $23.50 | 2019 | |
| Cycle Pharmaceuticals INC | $22.52 | 2024 | Sajazir |
| Verona Pharma, INC. | $20.47 | 2025 | Ohtuvayre |
| Alnylam Pharmaceuticals INC. | $19.67 | 2022 | |
| Dermavant Sciences, INC. | $19.54 | 2024 | Vtama |
| Insmed, INC. | $18.91 | 2024 | Arikayce |
| Galderma Laboratories, L.P. | $17.27 | 2025 | Nemluvio |
| Horizon Therapeutics Plc | $16.52 | 2022 | |
| Seqirus USA INC | $15.99 | 2022 | |
| Hospira, INC. | $14.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Howe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.